The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

被引：68

作者：

Ducreux, M. ^{[1
]}

Abou-Alfa, G. K. ^{[2
,3
,4
]}

Bekaii-Saab, T. ^{[5
]}

Berlin, J. ^{[6
]}

Cervantes, A. ^{[7
]}

de Baere, T. ^{[1
]}

Eng, C.

Galle, P. ^{[8
]}

Gill, S. ^{[9
]}

Gruenberger, T. ^{[10
,11
]}

Haustermans, K. ^{[12
,13
]}

Lamarca, A. ^{[14
,15
,16
]}

Laurent-Puig, P. ^{[17
]}

Llovet, J. M. ^{[18
,19
,20
]}

Lordick, F. ^{[21
]}

Macarulla, T. ^{[22
,23
]}

Mukherji, D. ^{[24
]}

Muro, K. ^{[25
]}

Obermannova, R. ^{[26
]}

O'Connor, J. -M. ^{[27
]}

O'Reilly, E. M. ^{[2
,3
]}

Osterlund, P. ^{[28
,29
]}

Philip, P. ^{[30
,31
]}

Prager, G. ^{[32
]}

Ruiz-Garcia, E. ^{[33
]}

Sangro, B. ^{[34
,35
]}

Seufferlein, T. ^{[36
]}

Tabernero, J. ^{[22
,23
]}

Verslype, C. ^{[12
,13
]}

Wasan, H. ^{[37
]}

Van Cutsem, E. ^{[12
,13
]}

机构：

[1] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Weill Cornell Coll Med, New York, NY USA

[4] Trinity Coll Dublin, Dublin, Ireland

[5] Mayo Clin, Canc Ctr, Phoenix, AZ USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Univ Valencia, Hosp Clin Univ, Biomed Res Inst, INCLIVA, Valencia, Spain

[8] Univ Med Ctr Mainz, Mainz, Germany

[9] BC Canc Univ British Columbia, Vancouver, BC, Canada

[10] HPB Ctr Hlth Network Vienna, Clin Favoriten, Vienna, Austria

[11] Sigmund Freud Univ, Med Sch, Vienna, Austria

[12] Univ Hosp Gasthuisbergs, Leuven, Belgium

[13] Katholieke Univ Leuven, Leuven, Belgium

[14] Fdn Jimenez Diaz Univ Hosp, OncoHealth Inst, Dept Oncol, Madrid, Spain

[15] Christie NHS Fdn, Dept Med Oncol, Manchester, England

[16] Univ Manchester, Div Canc Sci, Manchester, England

[17] Univ Paris Cite, Georges Pompidou Hosp, AP HP, Inst Canc Paris CARPEM, Paris, France

[18] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, New York, NY USA

[19] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer Hosp Clin, Barcelona, Spain

[20] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain

[21] Univ Leipzig, Comprehens Canc Ctr Cent Germany, Med Ctr, Leipzig, Germany

[22] Vall dHebron Hosp Campus, Barcelona, Spain

[23] UVic UCC, Inst Oncol IOB Quiron, Barcelona, Spain

[24] Amer Univ Beirut, Beirut, Lebanon

[25] Aichi Canc Ctr Hosp, Nagoya, Japan

[26] Masaryk Univ, Masaryk Mem Canc Inst, Fac Med, Brno, Czech Republic

[27] Inst Alexander Fleming, Buenos Aires, DF, Argentina

[28] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden

[29] Univ Tampere, Tampere Univ Hosp, Tampere, Finland

[30] Wayne State Univ, Henry Ford Canc Inst, Dept Oncol, Detroit, MI USA

[31] Wayne State Univ, Henry Ford Canc Inst, Dept Pharmacol, Detroit, MI USA

[32] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

[33] Inst Nacl Cancerol, Mexico City, Mexico

[34] Clin Univ Navarra, Pamplona, Spain

[35] CIBEREHD, Pamplona, Spain

[36] Ulm Univ Hosp, Ulm, Germany

[37] Imperial Coll London, Hammersmith Hosp, London, England

来源：

ESMO OPEN | 2023年 / 8卷 / 03期

关键词：

hepatocellular carcinoma; liver transplantation; chemoembolisation; immunotherapy; radioembolisation; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; STEREOTACTIC BODY RADIOTHERAPY; ATEZOLIZUMAB PLUS BEVACIZUMAB; LIVER-TRANSPLANTATION; RADIOFREQUENCY ABLATION; PHASE-III; SYSTEMIC TREATMENT; DOUBLE-BLIND; HCC; MULTICENTER;

D O I：

10.1016/j.esmoop.2023.101567

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

引用

页数：11

共 81 条

[1] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Abou-Alfa, Ghassan K.
Chan, Stephen Lam
Kudo, Masatoshi
Lau, George
Kelley, Robin Kate
Furuse, Junji
Sukeepaisarnjaroen, Wattana
Kang, Yoon-Koo
Dao, Tu V.
De Toni, Enrico N.
Rimassa, Lorenza
Breder, Valeriy Vladimirovich
Vasilyev, Alexander
Heurgue, Alexandra
Tam, Vincent
Mody, Kabir
Thungappa, Satheesh Chiradoni
He, Philip
Negro, Alejandra
Sangro, Bruno
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2] Cabozantinib in Hepatocellular Carcinoma Reply
Abou-Alfa, Ghassan K.
Borgman-Hagey, Anne E.
Kelley, Robin K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14) : 1384 - 1385
[3] ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC), US
[4] Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
Ayuso, Carmen
Rimola, Jordi
Vilana, Ramon
Burrel, Marta
Darnell, Anna
Garcia-Criado, Angeles
Bianchi, Luis
Belmonte, Ernest
Caparroz, Carla
Barrufet, Marta
Bruix, Jordi
Bru, Concepcion
[J]. EUROPEAN JOURNAL OF RADIOLOGY, 2018, 101 : 72 - 81
[5] Hepatocellular carcinoma: a review
Balogh, Julius
Victor, David, III
Asham, Emad H.
Burroughs, Sherilyn Gordon
Boktour, Maha
Saharia, Ashish
Li, Xian
Ghobrial, R. Mark
Monsour, Howard P., Jr.
[J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 41 - 53
[6] Combined hepatocholangiocarcinoma: Case-series and review of literature
Bhagat V.
Javle M.
Yu J.
Agrawal A.
Gibbs J.F.
Kuvshinoff B.
Nava E.
Iyer R.
[J]. International Journal of Gastrointestinal Cancer, 2006, 37 (1): : 27 - 34
[7] TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
Brown, Andrew M.
Kassab, Ihab
Massani, Marco
Townsend, Whitney
Singal, Amit G.
Soydal, Cigdem
Moreno-Luna, Laura
Roberts, Lewis R.
Chen, Vincent L.
Parikh, Neehar D.
[J]. CANCER MEDICINE, 2023, 12 (03): : 2590 - 2599
[8] Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
Brown, Karen T.
Do, Richard K.
Gonen, Mithat
Covey, Anne M.
Getrajdman, George I.
Sofocleous, Constantinos T.
Jarnagin, William R.
D'Angelica, Michael I.
Allen, Peter J.
Erinjeri, Joseph P.
Brody, Lynn A.
O'Neill, Gerald P.
Johnson, Kristian N.
Garcia, Alessandra R.
Beattie, Christopher
Zhao, Binsheng
Solomon, Stephen B.
Schwartz, Lawrence H.
DeMatteo, Ronald
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) : 2046 - +
[9] Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, Jordi
Chan, Stephen L.
Galle, Peter R.
Rimassa, Lorenza
Sangro, Bruno
[J]. JOURNAL OF HEPATOLOGY, 2021, 75 (04) : 960 - 974
[10] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruix, Jordi
Qin, Shukui
Merle, Philippe
Granito, Alessandro
Huang, Yi-Hsiang
Bodoky, Gyrogy
Pracht, Marc
Yokosuka, Osamu
Rosmorduc, Olivier
Breder, Valeriy
Gerolami, Rene
Masi, Gianluca
Ross, Paul J.
Song, Tianqiang
Bronowicki, Jean-Pierre
Ollivier-Hourmand, Isabelle
Kudo, Masatoshi
Cheng, Ann-Lii
Llovet, Josep M.
Finn, Richard S.
LeBerre, Marie-Aude
Baumhauer, Annette
Meinhardt, Gerold
Han, Guohong
[J]. LANCET, 2017, 389 (10064) : 56 - 66

← 1 2 3 4 5 6 7 8 9 →